share_log

MediWound to Report Third Quarter 2024 Financial Results

MediWound to Report Third Quarter 2024 Financial Results

mediwound將公佈2024年第三季度財務業績
GlobeNewswire ·  11/12 21:00

Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time

會議通話和網絡直播安排於2024年11月26日,美國東部時間上午8:30。

YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024.

以色列雅夫內,2024年11月12日,環球新聞社報道 -- mediwound有限公司(納斯達克股票代碼:MDWD)是生物製品行業的全球領先者,專注於下一代酶治療技術,用於組織修復。今天宣佈,將於2024年11月26日星期二發佈截至2024年9月30日第三季度的財務業績。

Following the release, MediWound's management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financial results and provide corporate updates.

在發佈後,mediwound的管理層將主持美國東部時間上午8:30的電話會議和現場網絡直播,討論財務業績並提供公司更新。

Dial-in and call details are as follows:

撥入和呼叫詳細信息如下:

Conference Call & Webcast Details
Toll-Free: 1-833-630-1956
Israel: 1-80-921-2373
International: 1-412-317-1837
Webcast: Click HERE
電話會議和網絡研討會詳情
免費電話: 1-833-630-1956
以色列: 1-80-921-2373
國際: 1-412-317-1837
網絡直播: 點擊這裏

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call. An archived version of the webcast will be available for replay on the Investors section of the MediWound website.

參與者應在電話會議開始前至少5分鐘撥打上述適用的電話號碼以查看看漲。MediWound網站的投資者部分將提供網頁播客的存檔版本供重播。

About MediWound

關於mediwound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of innovative biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.

mediwound有限公司(納斯達克代碼:MDWD)是全球下一代酶治療領域的領導者,專注於非手術組織修復。公司專注於開發、生產和商業化創新生物製品,提升現有護理標準,改善患者體驗,同時降低醫療成本和不必要的手術。

MediWound's first drug, NexoBrid, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Leveraging its proprietary enzymatic technology, MediWound is advancing EscharEx, a promising candidate currently in Phase III development for the debridement of chronic wounds. Phase II clinical trials have shown EscharEx has distinct advantages over the current $360+ million market leader, presenting a unique opportunity for significant market growth.

mediwound的首個藥物NexoBrid是FDA和EMA批准的孤兒藥物,用於深部部分厚度和/或全厚度燒傷的壞死組織去除,可顯著減少手術干預的需要。憑藉其專有的酶技術,mediwound正在推進EscharEx,這是一種有望通過III期研發用於慢性傷口去死組織的候選藥。II期臨床試驗表明EscharEx相較於目前市場領導者的36億美元具有獨特優勢,爲顯著市場增長提供了獨特機會。

For more information visit and follow us on LinkedIn.

獲取更多信息,請訪問和我們一起領英.

MediWound Contacts:
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com daniel@lifesciadvisors.com
Media Contact:
Ellie Hanson
FINN Partners for MediWound
ellie.hanson@finnpartners.com
+1-929-588-2008
mediwound聯繫人:
Hani Luxenburg Daniel Ferry
首席財務官 董事總經理
MediWound Ltd. LifeSci Advisors,LLC
ir@mediwound.com daniel@lifesciadvisors.com
媒體聯繫:
Ellie Hanson
MediWound的FINN合作伙伴
ellie.hanson@finnpartners.com
+1-929-588-2008

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論